Work Here?
Overview
Synonym.bio builds and manages biomanufacturing infrastructure by constructing new production facilities and leasing scalable microbial fermentation capacity to synthetic biology companies that lack the resources to build their own facilities, with minimal upfront capital. It operates the facilities and offers asset management for investors, curating opportunities in biomanufacturing infrastructure and handling risk management. Unlike firms that only provide services or equipment, it combines facility development with investment financing for both startup tenants and investors. Its goal is to expand scalable biomanufacturing capacity and help bring bio-based products to market while offering investors access to a growing asset class.
About Synonym
Industries
Venture Capital
Industrial & Manufacturing
Financial Services
Biotechnology
Company Size
1-10
Company Stage
Grant
Total Funding
$8.2M
Headquarters
New York City, New York
Founded
2021
Get referred to Synonym
See people who can refer or advise you
Simplify's Take
What believers are saying
- Synonym closed a $20 million Series A on October 22, 2025.
- Brenntag launched Better with Bio with Synonym on October 28, 2025.
- DoD's $1.89 million DBIMP award validates Synonym's infrastructure thesis and pipeline.
What critics are saying
- Facility economics hinge on finding viable sites before Series A capital runs thin.
- DBIMP follow-on awards depend on U.S. appropriations and defense prioritization through 2026.
- Synonym's rebrand to Roebling risks customer confusion and dilutes employer-brand continuity.
What makes Synonym unique
- Synonym pairs infrastructure development with data tools: Capacitor, Match, and Roebling.
- Its network model connects producers, manufacturers, buyers, and investors across biomanufacturing.
- The Brenntag and EuropaBio relationships broaden reach beyond single-facility project development.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$8.2M
Above
Industry Average
Funded Over
2 Rounds
Andreessen HorowitzBenefits
Health Insurance
Dental Insurance
Vision Insurance
Company Equity
Unlimited Paid Time Off
401(k) Retirement Plan
Company News
The alleywatch startup daily funding report: 11/5/2025. The latest venture capital, seed, pre-seed, and angel deals for NYC startups for 11/5/2025 featuring funding details for Teleskope, AUI, and much more. This page will be updated throughout the day to reflect any new fundings. Teleskope - $25M Series A. Teleskope, a data protection and security platform, has raised $25M in Series A funding led by M13. Founded by Elizabeth Nammour and Julie Trias in 2022, Teleskope has now raised a total of $32.2M in reported equity funding. AUI - $20M venture. AUI, the company building neuro-symbolic foundation models for task-oriented conversational AI, has raised $20M in Venture funding from investors that include New Era Capital Partners and eGateway Capital. Founded by Ohad Elhelo and Ori Cohen in 2017, AUI has now raised a total of $63.1M in reported equity funding. Synonym - $18.4M. Synonym, a platform for accelerating the launch and manufacturing of bioproducts, has raised $18.4M in funding according to a recent SEC filing. The filing indicates that the total offering is for $20.6M and there were fifty-two investors in this close. Synonym was founded by Edward Shenderovich and Joshua Lachter in 2021. Parable - $16.5M seed. Parable, an intelligence platform for enterprise operations, has raised $16.5M in Seed funding led by HOF Capital. Parable was founded by Adam Schwartz, Clinton Robinson, Alex Terrien, and Steve Tam in 2024. AlleyWatch is NYC's leading source of tech and startup news, reaching the city's most active founders, investors, and tech leaders. Advertise today iVerify - $12.3M. iVerify, a threat hunting platform for mobile devices, has raised $12.3M in funding according to a recent SEC filing. The filing indicates that there were six investors in the round. Founded by Danny Rogers and Rocky Cole in 2023, iVerify has now raised a total of $28.3M in reported equity funding. General Intelligence Company of New York - $10.4M. General Intelligence Company of New York, an AI platform that allows individuals to run entire businesses autonomously, has raised $10.4M in funding according to a recent SEC filing. The filing indicates that the total offering is for $11M and there were seven investors in this close. General Intelligence Company of New York was founded by Abhishyant Khare and Andrew Pignanelli in 2025. Cob Foods - $5M seed. Cob Foods, a sorghum-based snack brand, has raised $5M in Seed funding from investors that include Novak Djokovic. Cob Foods was founded by Jessica Brondo Davidoff and Djokovic in 2022. Helex - $3.5M seed. Helex, a therapeutics company focused on treatment of chronic and rare kidney disorders, has raised $3.5M in Seed funding led by Pi Ventures. Founded by Anirudh Nishtala, Poulami Chaudhuri, and Rohini Kalvakuntla in 2021, Helex has now raised a total of $4.6M in reported equity funding.
Schaumburg, Ill. — Primient, a leader in plant-based, renewable ingredients, and Synonym, a biomanufacturing infrastructure developer, today announced a strategic partnership to accelerate bioproduct innovation and commercialization, furthering the U.S.’ competitive advantage in the race...
Synonym Awarded $1.89 Million by the Department of Defense for Distributed Bioindustrial Manufacturing Program
Since insulin produced by genetically engineered bacteria—rather than the pancreases of slaughtered animals—was first approved in 1982, the market for ‘biomanufactured’ products produced by microbial, animal, or plant cells has grown rapidly. “But in areas other than pharma—whose business models are built on high-margin, low-volume products with low sensitivity to costs—innovations have created only niche markets in enzymes, fragrances, and food and feed supplements,” concedes a recent report from Synonym and Boston Consulting Group. So what will it take to make the economics of precision fermentation stack up for a wider range of bioproducts such that they can compete with low-margin, high volume products derived from petrochemicals or industrialized animal agriculture?
A recent report, co-authored by the New York-based biotech firm Synonym and Boston Consulting Group, has outlined a roadmap for the biomanufacturing industry, predicting a potential explosion to a $200 billion market in specialty sectors over the next ten years. The report Breaking the Cost Barrier on Biomanufacturing encourages the transition to biomanufacturing to address issues of sustainability and cost-efficiency in current industrial production methods. However, the report’s estimated $200 billion market value is focused on precision fermentation to produce food ingredients, chemicals, and chemical precursors. According to the authors, the figure is considered conservative and reflects only a fraction of the potential for growth within the industry
There are no jobs for Synonym right now.
Find jobs on Simplify and start your career today
About Synonym
Industries
Venture Capital
Industrial & Manufacturing
Financial Services
Biotechnology
Company Size
1-10
Company Stage
Grant
Total Funding
$8.2M
Headquarters
New York City, New York
Founded
2021
There are no jobs for Synonym right now.
Find jobs on Simplify and start your career today